A randomized pilot study to evaluate graft versus fistula vascular access strategy in older patients with advanced kidney disease: results of a feasibility study.

Arteriovenous vascular access Hemodialysis Kidney disease Older adults Randomized trial

Journal

Pilot and feasibility studies
ISSN: 2055-5784
Titre abrégé: Pilot Feasibility Stud
Pays: England
ID NLM: 101676536

Informations de publication

Date de publication:
2020
Historique:
received: 27 01 2020
accepted: 24 05 2020
entrez: 20 6 2020
pubmed: 20 6 2020
medline: 20 6 2020
Statut: epublish

Résumé

Although older adults encompass almost half of patients with advanced chronic kidney disease, it remains unclear which long-term hemodialysis vascular access type, arteriovenous fistula or arteriovenous graft, is optimal with respect to effectiveness and patient satisfaction. Clinical outcomes based on the initial AV access type have not been evaluated in randomized controlled trials. This pilot study tested the feasibility of randomizing older adults with advanced kidney disease to initial arteriovenous fistula versus graft vascular access surgery. Patients 65 years or older with pre-dialysis chronic kidney disease or incident end-stage kidney disease and no prior arteriovenous vascular access intervention were randomized in a 1:1 ratio to undergo surgical placement of a fistula or a graft after providing informed consent. Trial feasibility was evaluated as (i) recruitment of ≥ 70% of eligible participants, (ii) ≥ 50 to 70% of participants undergo placement of index arteriovenous access within 90 to 180 days of enrollment, respectively, (iii) ≥ 80% adherence to study-related assessments, and (iv) ≥ 70% of participants who underwent index arteriovenous access placement will have a follow-up duration of ≥ 12 months after index surgery date. Between September 2018 and October 2019, 81% (44/54) of eligible participants consented and were enrolled in the study; 11 had pre-dialysis chronic kidney disease, and 33 had incident or prevalent end-stage kidney disease. After randomization, 100% (21/21) assigned to arteriovenous fistula surgery and 78% (18/23) assigned to arteriovenous graft surgery underwent index arteriovenous access placement within a median (1st, 3rd quartile) of 5.0 (1.0, 14.0) days and 13.0 (5.0, 44.3) days, respectively, after referral to vascular surgery. The completion rates for study-specific assessments ranged between 40.0 and 88.6%. At median follow-up of 215.0 days, 5 participants expired, 7 completed 12 months of follow-up, and 29 are actively being followed. Assessments of grip strength, functional independence, and vascular access satisfaction were completed by > 85% of patients who reached pre-specified post-operative assessment time point. Results from this study reveal it is feasible to enroll and randomize older adults with advanced kidney disease to one of two different arteriovenous vascular access placement surgeries. The study can progress with minor protocol adjustments to a multisite clinical trial. Clinical Trials ID, NCT03545113.

Sections du résumé

BACKGROUND BACKGROUND
Although older adults encompass almost half of patients with advanced chronic kidney disease, it remains unclear which long-term hemodialysis vascular access type, arteriovenous fistula or arteriovenous graft, is optimal with respect to effectiveness and patient satisfaction. Clinical outcomes based on the initial AV access type have not been evaluated in randomized controlled trials. This pilot study tested the feasibility of randomizing older adults with advanced kidney disease to initial arteriovenous fistula versus graft vascular access surgery.
METHODS METHODS
Patients 65 years or older with pre-dialysis chronic kidney disease or incident end-stage kidney disease and no prior arteriovenous vascular access intervention were randomized in a 1:1 ratio to undergo surgical placement of a fistula or a graft after providing informed consent. Trial feasibility was evaluated as (i) recruitment of ≥ 70% of eligible participants, (ii) ≥ 50 to 70% of participants undergo placement of index arteriovenous access within 90 to 180 days of enrollment, respectively, (iii) ≥ 80% adherence to study-related assessments, and (iv) ≥ 70% of participants who underwent index arteriovenous access placement will have a follow-up duration of ≥ 12 months after index surgery date.
RESULTS RESULTS
Between September 2018 and October 2019, 81% (44/54) of eligible participants consented and were enrolled in the study; 11 had pre-dialysis chronic kidney disease, and 33 had incident or prevalent end-stage kidney disease. After randomization, 100% (21/21) assigned to arteriovenous fistula surgery and 78% (18/23) assigned to arteriovenous graft surgery underwent index arteriovenous access placement within a median (1st, 3rd quartile) of 5.0 (1.0, 14.0) days and 13.0 (5.0, 44.3) days, respectively, after referral to vascular surgery. The completion rates for study-specific assessments ranged between 40.0 and 88.6%. At median follow-up of 215.0 days, 5 participants expired, 7 completed 12 months of follow-up, and 29 are actively being followed. Assessments of grip strength, functional independence, and vascular access satisfaction were completed by > 85% of patients who reached pre-specified post-operative assessment time point.
CONCLUSIONS CONCLUSIONS
Results from this study reveal it is feasible to enroll and randomize older adults with advanced kidney disease to one of two different arteriovenous vascular access placement surgeries. The study can progress with minor protocol adjustments to a multisite clinical trial.
TRIAL REGISTRATION BACKGROUND
Clinical Trials ID, NCT03545113.

Identifiants

pubmed: 32551134
doi: 10.1186/s40814-020-00619-9
pii: 619
pmc: PMC7298797
doi:

Banques de données

ClinicalTrials.gov
['NCT03545113']

Types de publication

Journal Article

Langues

eng

Pagination

86

Subventions

Organisme : NIA NIH HHS
ID : R03 AG060178
Pays : United States

Informations de copyright

© The Author(s) 2020.

Déclaration de conflit d'intérêts

Competing interestsThe authors declare that they have no competing interests.

Références

J Vasc Access. 2009 Jul-Sep;10(3):199-202
pubmed: 19670174
Clin J Am Soc Nephrol. 2017 Jun 7;12(6):947-954
pubmed: 28522655
JAMA. 1963 Sep 21;185:914-9
pubmed: 14044222
Kidney Int. 2010 Jan;77(2):141-51
pubmed: 19907414
PLoS One. 2013 Aug 06;8(8):e68748
pubmed: 23936310
J Am Soc Nephrol. 2006 Nov;17(11):3204-12
pubmed: 16988062
Clin Geriatr Med. 2001 Aug;17(3):457-78, vi
pubmed: 11459715
Clin J Am Soc Nephrol. 2013 May;8(5):810-8
pubmed: 23371955
J Am Soc Nephrol. 2017 Feb;28(2):645-652
pubmed: 27605542
BMJ. 2011 Oct 18;343:d5928
pubmed: 22008217
Kidney Int. 2002 Aug;62(2):620-6
pubmed: 12110026
BMC Med Res Methodol. 2011 Aug 16;11:117
pubmed: 21846349
Clin J Am Soc Nephrol. 2007 Sep;2(5):1043-53
pubmed: 17702726
Nephrol Dial Transplant. 2014 May;29(5):990-6
pubmed: 23787545
J Vasc Surg. 2007 Feb;45(2):420-426
pubmed: 17264030
Ann Intern Med. 2007 Feb 6;146(3):177-83
pubmed: 17283348
Qual Life Res. 1994 Oct;3(5):329-38
pubmed: 7841967
Gerontologist. 1969 Autumn;9(3):179-86
pubmed: 5349366
Kidney Int. 2005 Jul;68(1):311-8
pubmed: 15954922
BMC Med Res Methodol. 2010 Jan 06;10:1
pubmed: 20053272
Semin Dial. 2002 Mar-Apr;15(2):116-20
pubmed: 11952939
Cardiovasc Eng Technol. 2017 Sep;8(3):244-254
pubmed: 28695442
J Gerontol A Biol Sci Med Sci. 2014 May;69(5):547-58
pubmed: 24737557
Clin J Am Soc Nephrol. 2011 Jul;6(7):1651-62
pubmed: 21734085
BMC Med Res Methodol. 2010 Jul 16;10:67
pubmed: 20637084
Contemp Clin Trials Commun. 2019 Apr 09;14:100357
pubmed: 31016270
Am J Kidney Dis. 2006 Jul;48 Suppl 1:S176-247
pubmed: 16813989
J Vasc Surg. 2018 May;67(5):1491-1500
pubmed: 29224945
Clin J Am Soc Nephrol. 2012 Jun;7(6):1039-46
pubmed: 22516288
J Vasc Surg. 2016 May;63(5):1326-32
pubmed: 26776449
PLoS Med. 2010 Mar 24;7(3):e1000251
pubmed: 20352064
Kidney Int. 2001 Oct;60(4):1443-51
pubmed: 11576358
Clin J Am Soc Nephrol. 2007 Jan;2(1):89-99
pubmed: 17699392
Am J Nephrol. 2019;49(1):11-19
pubmed: 30544112
Kidney Int. 2014 Jan;85(1):158-65
pubmed: 23802192
J Vasc Access. 2015 May-Jun;16(3):200-5
pubmed: 25634153

Auteurs

Mariana Murea (M)

Department of Internal Medicine, Section on Nephrology, Wake Forest School of Medicine, Medical Center Boulevard, Winston-Salem, NC 27157-1053 USA.

Randolph L Geary (RL)

Department of Vascular and Endovascular Surgery, Wake Forest School of Medicine, Winston-Salem, NC USA.

Denise K Houston (DK)

Section on Gerontology and Geriatric Medicine, Wake Forest School of Medicine, Winston-Salem, NC USA.

Matthew S Edwards (MS)

Department of Vascular and Endovascular Surgery, Wake Forest School of Medicine, Winston-Salem, NC USA.

Todd W Robinson (TW)

Department of Internal Medicine, Section on Nephrology, Wake Forest School of Medicine, Medical Center Boulevard, Winston-Salem, NC 27157-1053 USA.

Ross P Davis (RP)

Department of Vascular and Endovascular Surgery, Wake Forest School of Medicine, Winston-Salem, NC USA.

Justin B Hurie (JB)

Department of Vascular and Endovascular Surgery, Wake Forest School of Medicine, Winston-Salem, NC USA.

Timothy K Williams (TK)

Department of Vascular and Endovascular Surgery, Wake Forest School of Medicine, Winston-Salem, NC USA.

Gabriela Velazquez-Ramirez (G)

Department of Vascular and Endovascular Surgery, Wake Forest School of Medicine, Winston-Salem, NC USA.

Benjamin Bagwell (B)

Department of Internal Medicine, Section on Nephrology, Wake Forest School of Medicine, Medical Center Boulevard, Winston-Salem, NC 27157-1053 USA.

Audrey B Tuttle (AB)

Department of Internal Medicine, Section on Nephrology, Wake Forest School of Medicine, Medical Center Boulevard, Winston-Salem, NC 27157-1053 USA.

Shahriar Moossavi (S)

Department of Internal Medicine, Section on Nephrology, Wake Forest School of Medicine, Medical Center Boulevard, Winston-Salem, NC 27157-1053 USA.

Michael V Rocco (MV)

Department of Internal Medicine, Section on Nephrology, Wake Forest School of Medicine, Medical Center Boulevard, Winston-Salem, NC 27157-1053 USA.

Barry I Freedman (BI)

Department of Internal Medicine, Section on Nephrology, Wake Forest School of Medicine, Medical Center Boulevard, Winston-Salem, NC 27157-1053 USA.

Jeff D Williamson (JD)

Section on Gerontology and Geriatric Medicine, Wake Forest School of Medicine, Winston-Salem, NC USA.

Haiying Chen (H)

Department of Biostatistics and Data Science, Division of Public Health Sciences, Wake Forest School of Medicine, Winston-Salem, NC USA.

Jasmin Divers (J)

Division of Health Services Research, Department of Foundations of Medicine, NYU Long Island School of Medicine, Long Island, NY USA.

Classifications MeSH